MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s12885-024-11876-9

Медицинская библиотека · BMC cancer · 2024

Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study.

Qin Yan, Song Yongping, Wang Dong, Bai Ou, Feng Jifeng, Sun Xiuhua, Qiu Lihua, Yang Jianmin, Yang Yu, Wang Zhao, Hu Jianda, Wang Huaqing, Su Hang, Jin Zhengming, Qian Wenbin, Jin Chuan, Zhang Mingzhi, Yu Ding, Liu Li, Chen Guoan, Li Yarong, Sun Tao, Jin Jie, Bao Huizheng, Du Xin, Zhou Hui, Fu Gan, Shi Yuankai

Рандомизированное исследованиеСтатьяПеревод в очереди

Аннотация

HLX01 (HanliKang®) is a rituximab biosimilar that showed bioequivalence to reference rituximab in untreated CD20-positive diffuse large B-cell lymphoma (DLBCL) in the phase 3 HLX01-NHL03 study. Here, we report the 5-year follow-up results from the open-label extension part. Patients were randomised to either rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or HLX01 plus CHOP (H-CHOP) every 21 days for up to six cycles. The primary efficacy endpoint was overall survival (OS), and secondary efficacy endpoint was progression-free survival (PFS). Of the 407 patients enrolled in HLX01-NHL03, 316 patients (H-CHOP = 157; R-CHOP = 159) were included in the 5-year follow-up for a median duration of 65.1 (range, 2.2-76.5) months. 96.5% of the patients had an International Prognostic Index (IPI) of 1 or 2, and 17.7% had bone marrow involvement. The 5-year OS rates were 81.0% (95% CI: 74.9-87.5%) and 75.4% (95% CI: 68.9-82.6%)( HR: 0.75, 95% CI 0.47-1.20; p = 0.23) while 5-year PFS rates were 77.7% (95% CI: 71.4-84.6%) and 73.0% (95% CI: 66.3-80.3%) (HR: 0.84, 95% CI 0.54-1.30; p = 0.43) in the H-CHOP and R-CHOP groups, respectively. Treatment outcomes did not differ between groups regardless of IPI score and were consistent with the primary analysis. H-CHOP and R-CHOP provided no significant difference in 5-year OS or PFS in previously untreated patients with low or low-intermediate risk DLBCL.

Для цитирования: Qin Yan, Song Yongping, Wang Dong, Bai Ou, Feng Jifeng, Sun Xiuhua, Qiu Lihua, Yang Jianmin, Yang Yu, Wang Zhao, Hu Jianda, Wang Huaqing, Su Hang, Jin Zhengming, Qian Wenbin, Jin Chuan, Zhang Mingzhi, Yu Ding, Liu Li, Chen Guoan, Li Yarong, Sun Tao, Jin Jie, Bao Huizheng, Du Xin, Zhou Hui, Fu Gan, Shi Yuankai. Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study.. BMC cancer. 2024. DOI: 10.1186/s12885-024-11876-9.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.